Arrowhead, Sarepta Skyrocket

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, Sarepta will pay Arrowhead $500 million upfront and make a $325 million equity investment to gain access to Arrowhead's gene silencing technologies,
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets
Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and
Sarepta Therapeutics’ Strategic Partnership with Arrowhead Signals Strong Growth Prospects: A Buy Recommendation
Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...
FierceBiotech8h
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
STAT23h
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Sarepta股价因美银美林看好前景而上涨
周二，美银美林维持对Sarepta Therapeutics (NASDAQ:SRPT)的积极立场，重申"优于大市"评级，目标价为$200.00。该公司的乐观情绪源于Sarepta最近与Arrowhead达成的全球许可和合作协议，预计这将显著增强Sarepta的产品管线。
Business Insider16h
Sarepta Therapeutics Announces Leadership Change and Equity Deal
Don't Miss our Black Friday Offers: An announcement from Sarepta Therapeutics ( (SRPT)) is now available. Sarepta Therapeutics is undergoing a leadership change as Ryan Brown steps down, with ...
Analyst Expectations For Sarepta Therapeutics's Future
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...
Stocktwits on MSN9h
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High
Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...